stockrowVir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) Return on assets
Vir Biotechnology, Inc.'s return on assets over the twelve months to 30 September 2026 was −17.3%, up 19.1 percentage points from fiscal 2025 (−36.5%). Over the past ten years it has ranged from −121.0% (fiscal 2018) to 36.8% (fiscal 2021); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of −45.5% and above the Healthcare sector median of −28.8%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −36.5% | (5.01) |
| FY2024 | −31.5% | (5.40) |
| FY2023 | −26.1% | (47.75) |
| FY2022 | 21.7% | (15.11) |
| FY2021 | 36.8% | 78.55 |
| FY2020 | −41.8% | 7.90 |
| FY2019 | −49.7% | 71.32 |
| FY2018 | −121.0% | (89.51) |
| FY2017 | −31.5% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ZYME Zymeworks Inc. compare | 5.50% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| VIR Vir Biotechnology, Inc. | −17.3% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −27.8% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −36.3% |
| IMNM Immunome, Inc. compare | −70.2% |
| REPL Replimune Group, Inc. compare | −71.0% |
| BHVN Biohaven Ltd. compare | −161.3% |
| Biotechnology industry median | −45.5% |
| Healthcare sector median | −28.8% |
| Market median | 0.07% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on VIR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement